Should You Buy the Dip in Novo Nordisk Stock Right Now?
What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...
Tirzepatide outpacing Wegovy in the obesity space
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...
The Economist5h
To see what European business could become, look to the Nordics
The rest of Europe could learn from them. Politicians in Brussels are perpetually searching for ways to invigorate the ...
Hosted on MSN26m
Elon Musk Weighs In on Weight-Loss Drug Stocks. Is LLY or NVO a Better Buy?
Weight-loss drug stocks were catapulted into the spotlight in 2024, creating a lucrative, groundbreaking, and high-stakes ...
Drug firms amp up hiring for top roles as growth beckons
The proposed Biosecure Act as well as the diversification of American and European firms away from China are expected to help ...
clinicaltrialsarena4h
Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst
According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound will overtake competitors.
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.
thedailyupside8h
2025 is the Year of the Weight Loss Pill
Traditionally, New Year’s resolutions to lose weight involve getting to the gym more. In a post-GLP-1 world, that’s looking ...
yr.no19h
Novo Mesto
It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...